AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Key therapeutic areas include CNS, infectious disease and inflammation.

The Company’s lead product candidate is Zysolin™, an inhaled formulation of Tobramycin nanoparticles, intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in intubated and mechanically-ventilated patients (VAP); Vansolin™ and a Vancomycin compound encapsulated in the company's Nano Drug Delivery Platform intended for the treatment of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA).

AlphaRx’s goal is to become a world leader in the development of nano-medicine for critical illnesses and cancers. AlphaRx is poised to be the world’s first pharmaceutical company to commercialize a polymeric-based nanoparticulate antibiotic for the treatment of nosocomial pneumonia.    more...